Drugs / iron hydroxide adipate tartrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05950841 | Mar 2024 → Feb 2025 | iron deficiency anemia | RDC Clinical Pty Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iron hydroxide adipate tartrate | “orally-dosed IHAT (iron hydroxide adipate tartrate) at 2 different doses compared to placebo” NCT05950841 ↗ |
| Known as | IHAT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05950841 ↗ |
| Route | Oral | “orally-dosed IHAT” NCT05950841 ↗ |